Background: Brilliant blue G (BBG) is frequently used in chromovitrectomy to facilitate internal limiting membrane (ILM) peeling. A study was initiated to evaluate if heavy BBG is safe and effective in staining the ILM. Methods: We studied 30 eyes, 23 with idiopathic macular holes and 7 of patients with diabetic macular edema. Removal of the ILMs was assisted by heavy BBG staining. In cases with histopathological correlation the ILMs were evaluated with hematoxylin and eosin, Masson’s trichrome, periodic acid-Schiff and glial fibrillary acidic protein staining. In addition, immunohistochemistry was also performed using specific antibodies for vimentin, neuron-specific enolase, factor VIII and CD68. Using the Image-Pro Plus software of Media Cybernetics Co. we found an average thickness in ILMs. Results: Of the ILM specimens sent, 19/30 (63.33%) could not be processed properly because of the limited sample material, recognizing only fragments of dispersed fibrillar material. In macular hole ILMs we found an average thickness of 1.3 ± 0.65 µm, and in diabetic macular edema ILMs an average thickness of 6.2 ± 1.4 µm. Conclusions: In heavy BBG-assisted ILM peeling we observed no intraoperative or postoperative complications after a mean follow-up of 12 months. Heavy BBG could be an effective and safe vehicle for staining the ILM.

Journal Section:
Paper
Keywords:
Heavy brilliant blue G, Internal limiting membrane, Immunohistochemistry
1.
Brooks HL Jr: Macular hole surgery with and without internal limiting membrane peeling. Ophthalmology 2000;107:1939–1948.
[PubMed]
https://doi.org/10.1016%2FS0161-6420%2800%2900331-6
2.
Kuhn F: Point: to peel or not to peel, that is the question. Ophthalmology 2002;109:9–11.
[PubMed]
https://doi.org/10.1016%2FS0161-6420%2801%2900992-7
3.
Burk SE, da Mata AP, Synder ME, Rosa RH Jr, Foster RE: Indocyanine green-assisted peeling of the retinal internal limiting membrane. Ophthalmology 2000;107:2010–2014.
[PubMed]
https://doi.org/10.1016%2FS0161-6420%2800%2900375-4
4.
Kadonosono K, Itoh N, Uchio E, Nakamura S, Ohno S: Staining of the internal limiting membrane in macular hole surgery. Arch Ophthalmol 2000;118:1116–1118.
[PubMed]
5.
Enaida H, Sakamoto T, Hisatomi T, Goto Y, Ishibashi T: Morphological and functional damage of the retina caused by intravitreous indocyanine in rat eyes. Graefes Arch Clin Exp Ophthalmol 2002;240:209–213.
[PubMed]
https://doi.org/10.1007%2Fs00417-002-0433-7
6.
Sippy BD, Engelbrecht NE, Hubbard GB, Moriarty SE, Jiang S, Aaberg TM Jr, Aaberg TM Sr, Grossniklaus HE, Sternberg P Jr: Indocyanine green effect on cultured human retinal pigment epithelial cells: implication for macular hole surgery. Am J Ophthalmol 2001;132:433–435.
[PubMed]
https://doi.org/10.1016%2FS0002-9394%2801%2901061-3
7.
Stalmans P, Van Aken EH, Veckeneer M, Feron EJ, Stalmans I: Toxic effect of indocyanine green on retinal pigment epithelium related to osmotic effects of the solvent. Am J Ophthalmol 2002;134:282–285.
[PubMed]
https://doi.org/10.1016%2FS0002-9394%2802%2901468-X
8.
Gandorfer A, Haritoglou C, Gass CA, Ulbig MW, Kampik A: Indocyanine green-assisted peeling of the internal limiting membrane may cause retinal damage. Am J Ophthalmol 2001;132:431–433.
[PubMed]
https://doi.org/10.1016%2FS0002-9394%2801%2901087-X
9.
Haritoglou C, Gandorfer A, Gass CA, Schaumberger M, Ulbig MW, Kampik A: Indocyanine green-assisted peeling of the internal limiting membrane in macular hole surgery affects visual outcome: a clinicopathologic correlation. Am J Ophthalmol 2002;134:836–841.
[PubMed]
https://doi.org/10.1016%2FS0002-9394%2802%2901816-0
10.
Uemura A, Kanda S, Sakamoto Y, Kita H: Visual field defects after uneventful vitrectomy for epiretinal membrane with indocyanine green-assisted internal limiting membrane peeling. Am J Ophthalmol 2003;136:252–257.
[PubMed]
https://doi.org/10.1016%2FS0002-9394%2803%2900157-0
11.
Haritoglou C, Eibl K, Schaumberger M, Mueller AJ, Priglinger S, Alge C, Kampik A: Functional outcome after trypan blue-assisted vitrectomy for macular pucker: a prospective, randomized, comparative trial. Am J Ophthalmol 2004;138:1–5.
[PubMed]
https://doi.org/10.1016%2Fj.ajo.2004.03.005
12.
Veckeneer M, van Overdam K, Monzer J, Kobuch K, van Marle W, Spekreijse H, van Meurs J: Ocular toxicity study of trypan blue injected into the vitreous cavity of rabbit eyes. Graefes Arch Clin Exp Ophthalmol 2001;239:698–704.
[PubMed]
https://doi.org/10.1007%2Fs004170100341
13.
Lüke M, Januschowski K, Beutel J, Lüke C, Grisanti S, Peters S, Jaissle GB, Bartz-Schmidt KU, Szurman P: Electrophysiological effects of brilliant blue G in the model of the isolated per fused vertebrate retina. Graefes Arch Clin Exp Ophthalmol 2008;246:817–822.
[PubMed]
https://doi.org/10.1007%2Fs00417-007-0761-8
14.
Ueno A, Hisatomi T, Enaida H, Kagimoto T, Mochizuki Y, Goto Y, Kubota T, Hata Y, Ishibashi T: Biocompatibility of brilliant blue G in a rat model of subretinal injection. Retina 2007;27:499–504.
[PubMed]
https://doi.org/10.1097%2FIAE.0b013e318030a129
15.
Enaida H, Hisatomi T, Goto Y, Hata Y, Ueno A, Miura M, Kubota T, Ishibashi T: Preclinical investigation of internal limiting membrane peeling and staining using intravitreal brilliant blue G. Retina 2006;26:623–630.
[PubMed]
https://doi.org/10.1097%2F00006982-200607000-00006
16.
Eckardt C Eckardt U, Groos S, Luciano L, Reale E: Removal of the internal limiting membrane in macular holes: clinical and morphological findings. Ophthalmologe 1997;94:545–551.
[PubMed]
https://doi.org/10.1007%2Fs003470050156
17.
Hartley KL, Smiddy WE, Flynn HW Jr, Murray TG: Pars plana vitrectomy with internal limiting membrane peeling for diabetic macular edema. Retina 2008;28:410–419.
[PubMed]
https://doi.org/10.1097%2FIAE.0b013e31816102f2
18.
Park DH, Kim IT: Long-term effects of vitrectomy and internal limiting membrane peeling for macular edema secondary to central retinal vein occlusion and hemiretinal vein occlusion. Retina 2010;30:117–124.
[PubMed]
https://doi.org/10.1097%2FIAE.0b013e3181bced68
19.
Haritoglou C, Gandorfer A, Schaumberger M, Priglinger SG, Mueller AJ, Gass CA, Kampik A: Trypan blue in macular pucker surgery: an evaluation of histology and functional outcome. Retina 2004;24:582–590.
[PubMed]
https://doi.org/10.1097%2F00006982-200408000-00012
20.
Rodrigues EB, Costa EF, Penha FM, Melo GB, Bottós J, Dib E, Furlani B, Lima VC, Maia M, Meyer CH, Höfling-Lima AL, Farah ME: The use of vital dyes in ocular surgery. Surv Ophthalmol 2009;54:576–617.
https://doi.org/10.1016%2Fj.survophthal.2009.04.011
21.
Enaida H, Hisatomi T, Hata Y, Ueno A, Goto Y, Yamada T, Kubota T, Ishibashi T: Brilliant blue G selectively stains the internal limiting membrane/brilliant blue G-assisted membrane peeling. Retina 2006;26:631–636.
[PubMed]
https://doi.org/10.1097%2F00006982-200607000-00007
22.
Hisatomi T, Enaida H, Matsumoto H, Kagimoto T, Ueno A, Hata Y, Kubota T, Goto Y, Ishibashi T: Staining ability and biocompatibility of brilliant blue G: preclinical study of brilliant blue G as an adjunct for capsular staining. Arch Ophthalmol 2006;124:514–519.
[PubMed]
https://doi.org/10.1001%2Farchopht.124.4.514
23.
Remy M, Thaler S, Schumann RG, May CA, Fiedorowicz M, Schuettauf F, Grüterich M, Priglinger SG, Nentwich MM, Kampik A, Haritoglou C: An in vivo evaluation of brilliant blue G in animals and humans. Br J Ophthalmol 2008;92:1142–1147.
[PubMed]
https://doi.org/10.1136%2Fbjo.2008.138164
24.
Haritoglou C, Schumann RG, Kampik A, Gandorfer A: Heavy brilliant blue G for internal limiting membrane staining. Retina 2011;31:405–407.
https://doi.org/10.1097%2FIAE.0b013e3181feccd7
25.
Gerding H, Timmermann M, Thelen U: Intravital staining of the internal limiting membrane with a novel heavy solution of brilliant blue G. Klin Monbl Augenheilkd 2011;228:298–301.
https://doi.org/10.1055%2Fs-0031-1273213
© 2012 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2012
You do not currently have access to this content.